Advances in Anticancer Drug Metabolism Research: Implications for Personalized Therapeutics
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".
Deadline for manuscript submissions: closed (31 October 2025) | Viewed by 1975
Special Issue Editors
Interests: cardio-oncology; anticancer drugs; cardiotoxicity; in vivo; in vitro; molecular biology; inflammation; oxidative stress; metabolism; biotransformation
Interests: pharmacology; metal-based drugs; in vitro; in vivo; oncology; pharmacokinetics; anticancer drugs; biomarkers
Special Issues, Collections and Topics in MDPI journals
Interests: toxicology; drugs of abuse; amphetamines; synthetic cathinones; psychoactive substances; toxicometabolomics; cancer metabolomics; biomarkers; hepatotoxicity; nephrotoxicity; cardiotoxicity; oxidative stress
Special Issues, Collections and Topics in MDPI journals
Interests: phenolic compounds; immunometabolism; food nanotechnologies; nanoencapsulation; drug delivery systems; biodisponibility; colorectal cancerolic compounds; persimmon; food science; functional foods; biochemistry; haematology; in vitro/in vivo inflammation and cancer models
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to the launch of a Special Issue titled "Advances in Anticancer Drug Metabolism Research: Implications for Personalized Therapeutics". This Special Issue aims to underscore the critical role of drug metabolism in determining the efficacy and safety of anticancer therapies. A deeper understanding of metabolic pathways and the genetic factors influencing drug biotransformation is essential for optimizing therapeutic outcomes and driving the development of personalized medicines.
We welcome original research articles and comprehensive reviews on a variety of topics, including, but not limited to, the following:
- Metabolic pathways of anticancer drugs;
- Pharmacogenomics and precision oncology;
- Drug–drug interactions in cancer therapies;
- Biomarkers of drug response and/or toxicity;
- Emerging therapeutic targets and innovative strategies.
Submissions exploring interdisciplinary approaches that increase our understanding of drug metabolism's impact on personalized cancer treatment are particularly welcome. These collaborations have the potential to drive significant advancements in improving patient outcomes, encompassing survival rates and quality of life.
We look forward to your contributions to this Special Issue, thus enhancing the field of anticancer drug metabolism research and its translation into tailored therapeutic strategies.
Dr. Ana Reis-Mendes
Dr. Martin Vojtek
Dr. Márcia Carvalho
Dr. Rosa Direito
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticancer drug metabolism
- personalized medicine
- drug interactions
- therapeutic efficacy
- drug safety
- pharmacogenomics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
